What You Should Know:
– Labcorp, a global leader in innovative laboratory services, and Hawthorne Effect, Inc., a pioneer in technology-driven clinical trial solutions, have announced a groundbreaking partnership to revolutionize clinical trials with a focus on decentralization.
– This collaboration aims to unlock unprecedented levels of patient diversity, reduce site burden, and accelerate study timelines for pharmaceutical, biotech, and medical device sponsors.
Decentralization: The Future of Clinical Trials
Traditional clinical trials often face limitations, including geographical restrictions, inconvenient patient travel, and underrepresentation of diverse populations. The Labcorp-Hawthorne Effect alliance tackles these challenges head-on by embracing decentralization. Hawthorne Effect’s cutting-edge digital platform allows complex study visits and data collection to be conducted seamlessly in patients’ homes or local communities.
This innovative approach offers a multitude of benefits:
– Increased Patient Diversity and Inclusion: Decentralization removes geographic barriers, making it easier for individuals from diverse backgrounds to participate in trials, leading to more representative study results.
– Reduced Site Burden: By shifting some responsibilities from traditional clinical sites to patients’ homes, the pressure on research centers is lessened, improving overall efficiency.
– Accelerated Enrollment and Timelines: The convenience and flexibility of decentralized trials can attract more participants and streamline study processes, leading to faster completion times.
“At Labcorp, we are committed to making life-saving clinical trials more accessible, diverse and inclusive to all communities,” said Jonathan DiVincenzo, Labcorp’s President of Central Laboratories and International. “Through this collaboration, we look forward to combining Labcorp’s global laboratory network and logistics capabilities with Hawthorne Effect’s digital platform to advance our decentralized clinical trial capabilities, increase clinical trial accessibility and diversity, and bring greater value to patients, their physicians and our sponsors.”
